EDUCATIONAL NOTICE: Peptidings provides information for educational and research purposes only. The compounds discussed on this page are subjects of ongoing scientific investigation at varying stages of development. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Browse by Condition
Gut Dysfunction
Gut health is one of the most common reasons people explore peptides—and one where the research landscape is unusually wide. It stretches from FDA-approved drugs (teduglutide for short bowel syndrome, secretin for pancreatic function testing) to community favorites with almost no human data (BPC-157, KPV), with a middle layer of clinically-advanced compounds that have run real trials but haven’t crossed the approval line (larazotide, ghrelin analogs).
This page collects every peptide on Peptidings with published research relevant to inflammatory bowel disease, intestinal barrier repair, gut motility, gut hormone signaling, and gastrointestinal dysfunction—regardless of which cluster the compound lives in.
Condition at a Glance
|
9 Compounds Researched |
2 FDA Approved |
2 Clinical Trials |
3 Pilot Data |
2 Preclinical |
|
Approved Drug FDA-approved or equivalent regulatory approval |
Clinical Trials Human clinical trial data (Phase I+) |
Pilot / Limited Human Data Small or preliminary human studies |
Preclinical Only Animal models and cell culture only |
BLUF: Bottom Line Up Front
The gut dysfunction landscape is the most tiered on Peptidings. Two compounds are FDA-approved for specific gut indications: teduglutide (Gattex) for short bowel syndrome, and secretin for diagnostic pancreatic function testing. Larazotide reached Phase 3 for celiac disease but missed its primary endpoint. Ghrelin analogs have advanced to Phase 3 for diabetic gastroparesis. BPC-157 has extensive rodent data and two small human IBD pilot studies using an oral formulation. KPV works in mice using a nanoparticle delivery system that consumers can’t access. LL-37 and glutathione play supporting roles in barrier defense and oxidative stress. Cholecystokinin is used diagnostically to provoke gallbladder contraction. None of the community-favored compounds have controlled trial data for the gut uses people pursue.
Compounds Researched for This Condition
9 compounds with published research relevant to gut dysfunction. Evidence tiers reflect the strength of research for this specific condition—not the compound’s highest overall tier.
Group 1 of 3
The Gut Repair Peptides
Compounds with direct mechanisms for gut tissue healing and intestinal barrier restoration.
Group 2 of 3
The Gut Barrier & Defense Compounds
Compounds that regulate intestinal permeability, antimicrobial defense, and oxidative protection of the gut barrier.
|
|
|
Group 3 of 3
The Gut Signaling Hormones
Endogenous gut peptide hormones that regulate digestion, motility, secretion, and mucosal growth—some with FDA-approved therapeutic or diagnostic uses.
|
|
|
||||||||||||
|
What the Research Landscape Looks Like
The gut dysfunction evidence landscape is unusual because it spans every evidence tier at once. On one end, teduglutide has FDA approval and years of clinical use for short bowel syndrome—a genuine peptide drug with a real therapeutic record. Secretin has decades of diagnostic use for pancreatic function testing. On the other end, BPC-157 has a massive preclinical rodent literature and two small human pilot studies, neither of which were controlled trials. In between sits larazotide—which ran a full Phase 3 celiac trial and missed its primary endpoint, the closest any barrier-function peptide has come to approval.
KPV’s colitis data is mechanistically compelling—NF-κB suppression via oral nanoparticle delivery is elegant science. But the nanoparticle formulation is the critical variable, and it is not what consumers are purchasing. The gap between what was tested (encapsulated nanoparticles) and what is sold (plain peptide) may be the difference between efficacy and futility. Ghrelin analogs have advanced further in clinical development than most peptide categories—Phase 3 data for diabetic gastroparesis exists—but an approved drug hasn’t yet emerged from that pipeline.
| Mechanism | Compounds |
|
Gut Tissue Repair Accelerating healing of damaged intestinal mucosa—ulcers, inflammation, anastomosis sites, and mucosal regeneration. |
BPC-157, GLP-2 (Teduglutide) |
|
Tight Junction & Barrier Regulation Modulating the intestinal barrier by tightening the junctions between epithelial cells—reducing permeability in inflammatory and autoimmune gut conditions. |
Larazotide |
|
NF-κB Inflammatory Suppression Blocking the master inflammatory transcription factor that drives intestinal inflammation in IBD and colitis. |
KPV |
|
Antimicrobial Barrier Defense Killing gut pathogens and supporting the mucosal immune barrier that prevents bacterial translocation. |
LL-37 |
|
Antioxidant Protection Reducing oxidative damage in inflamed intestinal tissue—a feature of IBD and barrier dysfunction. |
Glutathione |
|
Gut Motility & Gastric Emptying Regulating the speed of gastric emptying and intestinal transit—relevant to gastroparesis, functional dyspepsia, and motility disorders. |
Ghrelin |
|
Pancreatic & Biliary Secretion Stimulating release of pancreatic bicarbonate, digestive enzymes, and bile—used diagnostically and for research into exocrine function. |
Secretin, Cholecystokinin (CCK) |
Plain English
Two of these compounds are actual FDA-approved gut drugs: teduglutide (sold as Gattex) treats short bowel syndrome, and secretin is used in hospitals to test pancreatic function. Larazotide got further in clinical trials than any other gut barrier peptide—but its big Phase 3 trial for celiac disease missed the mark in 2022. Ghrelin analogs have reached late-stage trials for gastroparesis. BPC-157 has tons of rodent data and two small human IBD studies using an oral form. KPV works in mice using a nanoparticle delivery system you can’t buy. LL-37 fights gut bacteria, glutathione handles oxidative stress, and CCK is mostly used in imaging. The gap between the approved drugs and the community-favorite peptides is wide, and the research tells different stories at different ends of it.
Related Research
Research Clusters Covering These Compounds
|
Gut Health Peptides The primary cluster for gut-focused peptides—larazotide, ghrelin, secretin, CCK, and teduglutide. |
Immune Health Peptides KPV and LL-37—immunomodulatory compounds with gut-relevant mechanisms. |
Injury Recovery & Tissue Repair BPC-157's home cluster—tissue repair compounds with gut healing applications. |
|
Anti-Aging & Longevity Glutathione—antioxidant tripeptide with relevance to oxidative gut damage. |
Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed are subjects of ongoing scientific research and have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.